Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-12-01

Clinical Trial Update: Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 [Phase 1]

View source ↗

Summary

Pfizer's Phase 1 multiple-oral-dose study of PF-04878691 for hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PF-04878691

Snippet

Sponsor: Pfizer | Conditions: Hepatitis C Virus | Phase 1 | Status: COMPLETED